Nasal delivery is a favorable route for vaccination against most respiratory infections, as antigen deposited in the nasal turbinate and Waldeyer’s ring areas induce mucosal and systemic immune responses. However, little is known about the nasal distribution of the vaccines, specifically for infants.
Anatomical nasal replicas of five subjects, 3–24 months, were developed to assess local intranasal vaccine delivery using MAD Nasal™ device, and understand impact of breathing conditions and administration parameters. High performance liquid chromatography was used to quantify the deposition pattern and determine the delivery efficiency.
The delivery efficiency on average for all models was found to be 86.57±14.23%. There were no significant differences in the total delivery efficiency between the models in all cases. However, the regional deposition pattern was altered based on the model and subsequent administration. Furthermore, removing the foam tip from the MAD Nasal™ device, to study the impact of insertion length, did not significantly increase the efficiency within the two models tested, 5- and 16-month.
Incorporating nasal replicas in testing provided a benchmark to determine the efficiency of a common intranasal vaccine delivery combination product. This proposed platform would allow comparing other potential nasal vaccine delivery devices.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
High performance liquid chromatography
Tukey’s honest significant difference test
Internal nasal valve
Mucosal atomization device
Nasal-associated lymphoid tissue
- RDE :
Regional deposition efficiency
- RDP Ad :
Adenoid regional deposition percentage
- RDP An :
Anterior regional deposition percentage
- RDP NC :
Nasal cavity regional deposition percentage
- RDP Ol :
Olfactory regional deposition percentage
- RDP PS :
Paranasal sinuses regional deposition percentage
- RDP TF :
Throat and filter regional deposition percentage
Yusuf H, Kett V. Current prospects and future challenges for nasal vaccine delivery. Hum Vaccines Immunother. 2017;13:34–45.
Sharma S, Mukkur TKS, Benson HAE, Chen Y. Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems. J Pharm Sci. 2009;98:812–43.
Zaman M, Chandrudu S, Toth I. Strategies for intranasal delivery of vaccines. Drug Deliv Transl Res. 2013;3:100–9.
Yuki Y, Kiyono H. Mucosal vaccines: novel advances in technology and delivery. Expert Rev Vaccines. 2009;8:1083–97.
Jabbal-Gill I. Nasal vaccine innovation. J Drug Target. 2010;18:771–86.
Giudice EL, Campbell JD. Needle-free vaccine delivery. Adv Drug Deliv Rev. 2006;58:68–89.
Illum L. Nasal drug delivery - possibilities, problems and solutions. J Control Release. 2003;87:187–98.
Tlaxca JL, Ellis S, Remmele RL. Live attenuated and inactivated viral vaccine formulation and nasal delivery: potential and challenges. Adv Drug Deliv Rev. 2015;93:56–78.
Riese P, Sakthivel P, Trittel S, Guzmán CA. Intranasal formulations: promising strategy to deliver vaccines. Expert Opin Drug Deliv. 2014;11:1619–34.
O’Hagan DT, Rappuoli R. Novel approaches to vaccine delivery. Pharm Res. 2004;21:1519–30.
Davis SS. Nasal vaccines. Adv Drug Deliv Rev. 2001;51:21–42.
Slütter B, Hagenaars N, Jiskoot W. Rational design of nasal vaccines. J Drug Target. 2008;16:1–17.
Djupesland PG. Nasal drug delivery devices: characteristics and performance in a clinical perspective-a review. Drug Deliv Transl Res. 2013;3:42–62.
Scherließ R. Nasal administration of vaccines. In: Foged C, Rades T, Perrie Y, Hook S, editors. Subunit vaccine Deliv Adv Deliv Sci Technol. New York: Springer; 2015.
Bryant ML, Brown P, Gurevich N, McDougall IR. Comparison of the clearance of radiolabelled nose drops and nasal spray as mucosally delivered vaccine. Nucl Med Commun. 1999;20:171–4.
Laube BL, Sharpless G, Vikani AR, Harrand V, Zinreich SJ, Sedberry K, et al. Intranasal deposition of Accuspray™ aerosol in anatomically correct models of 2-, 5-, and 12-year-old children. J Aerosol Med Pulm Drug Deliv. 2015;28:320–33.
Sosnowski TR, Rapiejko P, Sova J, Dobrowolska K. Impact of physicochemical properties of nasal spray products on drug deposition and transport in the pediatric nasal cavity model. Int J Pharm. Elsevier; 2020;574:118911.
Tripp RA, Hanson JM. Inhaled countermeasures for respiratory tract viruses. In: Kwok PCL, Chan H-K, editors. Adv Pulm Drug Deliv. Boca Raton: Taylor & Francis Group; 2016. p. 93–129.
Kundoor V, Dalby RN. Effect of formulation- and administration-related variables on deposition pattern of nasal spray pumps evaluated using a nasal cast. Pharm Res. 2011;28:1895–904.
Xi J, Yuan JE, Zhang Y, Nevorski D, Wang Z, Zhou Y. Visualization and quantification of nasal and olfactory deposition in a sectional adult nasal airway cast. Pharm Res. 2016;33:1527–41.
Foo MY, Cheng YS, Su WC, Donovan MD. The influence of spray properties on intranasal deposition. J Aerosol Med. 2007;20:495–508.
Hosseini S, Wei X, Wilkins JV, Fergusson CP, Mohammadi R, Vorona G, et al. In vitro measurement of regional nasal drug delivery with Flonase,® Flonase® Sensimist,™ and MAD Nasal™ in anatomically correct nasal airway replicas of pediatric and adult human subjects. J Aerosol Med Pulm Drug Deliv. 2019;32:374–85.
Storey-Bishoff J, Noga M, Finlay WH. Deposition of micrometer-sized aerosol particles in neonatal nasal airway replicas. J Aerosol Sci. 2008;39:1055–65.
Zhou Y, Guo M, Xi J, Irshad H, Cheng Y-S. Nasal deposition in infants and children. J Aerosol Med Pulm Drug Deliv. 2014;27:110–6.
Tavernini S, Church TK, Lewis DA, Noga M, Martin AR, Finlay WH. Deposition of micrometer-sized aerosol particles in neonatal nasal airway replicas. Aerosol Sci Technol 2017;0.
Laube BL, Sharpless G, Shermer C, Sullivan V, Powell K. Deposition of dry powder generated by Solovent in Sophia anatomical infant nose-throat (SAINT) model. Aerosol Sci Technol. 2011;46:514–20.
Hosseini S, Golshahi L. An in vitro evaluation of importance of airway anatomy in sub-regional nasal and paranasal drug delivery with nebulizers using three different anatomical nasal airway replicas of 2-, 5- and 50-year old human subjects. Int J Pharm. 2019;563:426–36.
Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol. 2006;6:148–58.
Borges O, Lebre F, Bento D, Borchard G, Junginger HE. Mucosal vaccines: recent progress in understanding the natural barriers. Pharm Res. 2010;27:211–23.
Si XA, Xi J, Kim JW, Zhou Y, Zhong H. Modeling of release position and ventilation effects on olfactory aerosol drug delivery. Respir Physiol Neurobiol. 2013;186:22–32.
Shang Y, Dong J, Inthavong K, Tu J. Comparative numerical modeling of inhaled micron-sized particle deposition in human and rat nasal cavities. Inhal Toxicol. 2015;27:694–705.
ICRP. Human Respiratory Tract Model for Radiological Protection. ICRP Publ 66. 1994;Ann. ICRP.
Debertin AS, Tschernig T, Tönjes H, Kleemann WJ, Tröger HD, Pabst R. Nasal-associated lymphoid tissue (NALT): frequency and localization in young children. Clin Exp Immunol. 2003;134:503–7.
Pabst R. Mucosal vaccination by the intranasal route. Nose-associated lymphoid tissue (NALT)-structure, function and species differences. Vaccine. Elsevier Ltd; 2015;33:4406–4413.
van Ginkel FW, Jackson RJ, Yuki Y, McGhee JR. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol United States. 2000;165:4778–82.
Fukuyama Y, Okada K, Yamaguchi M, Kiyono H, Mori K, Yuki Y. Nasal Administration of Cholera Toxin as a mucosal adjuvant damages the olfactory system in mice. PLoS One. 2015;10:e0139368.
Wewetzer K, Radtke C, Kocsis J, Baumgärtner W. Species-specific control of cellular proliferation and the impact of large animal models for the use of olfactory ensheathing cells and Schwann cells in spinal cord repair. Exp Neurol. Elsevier Inc.; 2011;229:80–7.
Brandes G, Khayami M, Peck CT, Baumgärtner W, Bugday H, Wewetzer K. Cell surface expression of 27C7 by neonatal rat olfactory ensheathing cells in situ and in vitro is independent of axonal contact. Histochem Cell Biol. 2011;135:397–408.
Amirav I, Borojeni AAT, Halamish A, Newhouse MT, Golshahi L. Nasal versus oral aerosol delivery to the “lungs” in infants and toddlers. Pediatr Pulmonol. 2015;50:276–83.
El Taoum KK, Xi J, Kim JW, Berlinski A. In vitro evaluation of aerosols delivered via the nasal route. Respir Care. 2015;60:1015–25.
Bergeson PS, Shaw JC. Are infants really obligatory nasal breathers? Clin Pediatr (Phila). 2001;40:567–9.
ACKNOWLEDGMENTS AND DISCLOSURE
Authors would like to acknowledge Yan-Ping Yang, Sebastien Carayol, and Scott Gallichan for their supports on this project. In addition, Sana Hosseini is acknowledged for her contributions to the development of the models and measurement of some anatomical dimensions. Dr. Joseph Turner is gratefully acknowledged for providing the analytical support through VCU Instrumentation Facility. The authors have no conflicts of interest to declare related to the subject of this manuscript. The content is solely the responsibility of the authors and does not necessarily represent the views of the sponsor and VCU.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Wilkins, J.V., Golshahi, L., Rahman, N. et al. Evaluation of Intranasal Vaccine Delivery Using Anatomical Replicas of Infant Nasal Airways. Pharm Res 38, 141–153 (2021). https://doi.org/10.1007/s11095-020-02976-9
- dose deposition
- intranasal vaccines
- in vitro
- nasal models